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Purpose:Many patients with ischemic stroke have concomitant coronary artery disease
(CAD). However, it remains unclear which stroke patients should undergo evaluation for
asymptomatic CAD, and which screening tools are appropriate. We investigated the role
of coronary artery calcium (CAC) score as a screening tool for asymptomatic but severe
CAD in acute stroke patients. We determined the selection criteria for CAC screening
based on risk factors and cerebral atherosclerosis.
Materials and Methods: The present study included consecutive patients with
acute stroke who had undergone cerebral angiography and multi-detector computed
tomography coronary angiography. Severe CAD was defined as left main artery disease
or three-vessel disease. Enrolled patients were randomly assigned to two sets; a
set for developing selection criteria and a set for validation. To develop selection
criteria, we identified associated factors with severe CAD regarding clinical factors and
cerebral atherosclerosis. CAD predictability of selection criteria with the CAC score
was calculated.
Results: Overall, 2,658 patients were included. Severe CAD was present in 360
patients (13.5%). CAC score was associated with CAD severity (P < 0.001). In the
development set (N = 1,860), severe CAD was associated with age >65 years
[odds ratio (95% confidence interval), 2.62 (1.93–3.55)], male sex (1.81 [1.33–2.46]),
dyslipidemia (1.77 [1.25–2.61]), peripheral artery disease (2.64 [1.37–5.06]) and stenosis
in the cervicocephalic branches, including the internal carotid (2.79 [2.06–3.78]) and
vertebrobasilar arteries (2.08 [1.57–2.76]). We determined the combination of clinical and
arterial factors as the selection criteria for CAC evaluation. The cut-off criterion was two
or more elements of the selection criteria. The area under the curve (AUC) of the selection
criteria was 0.701. The AUC significantly improved to 0.836 when the CAC score was
added (P < 0.001). In the validation set (N = 798), the AUC of the selection criteria only
Choi et al. CAC Screening in Cerebral Infarction
was 0.661, and that of the CAC score was 0.833. The AUC of the selection criteria +
CAC score significantly improved to 0.861(P < 0.001).
Conclusion: The necessity for CAC evaluation could be determined based on the
presence of risk factors and significant stenosis of the cervicocephalic arteries. CAC
evaluation may be useful for screening for severe CAD in stroke patients.
Keywords: cerebral infarction, coronary artery disease, coronary calcium score, atherosclerosis, risk factors
INTRODUCTION
Ischemic heart disease is the leading cause of long-termmortality
in patients with stroke (1). The annual risk of myocardial
infarction in patients with ischemic stroke is ∼2.2% (1, 2).
The presence and extent of asymptomatic stenosis in coronary
angiography is strongly predictive of major cardiovascular
events. Previous studies identified significant (≥50%) stenosis
of the coronary artery in 20–41% of patients with stroke via
autopsy, coronary angiography, or multi-detector computed
tomography angiography (MDCTA) (3–7). Therefore, coronary
screening may be necessary for stroke patients at high risk
of coronary artery disease (CAD). However, it still remains
uncertain which group of patients with stroke should undergo
evaluation for asymptomatic CAD, and which evaluation tools
are most appropriate for coronary screening in such patients.
Atherosclerosis is a systemic disease and CAD shares several
risk factors with cerebral atherosclerosis (8). In fact, previous
studies have demonstrated a significant association between CAD
and atherosclerosis of the cervicocephalic arteries including the
vertebrobasilar artery (VBA) and carotid arteries (4, 6, 9, 10).
These findings suggest that CAD may be predicted to some
extent by the presence of cerebral atherosclerosis and vascular
risk factors.
Previous studies have indicated that coronary artery calcium
(CAC) is superior to risk factor-based prediction of CAD and
coronary events (11–14). Additionally, other studies reported
that CAC scores are associated with the severity of CAD (15). In a
large prospective population cohort registry, the risk of coronary
events increased as the CAC score increased (12). This study
aimed to investigate the role of the CAC score as a screening tool
for the diagnosis of asymptomatic but severe CAD in patients
with acute stroke. We also sought to determine the selection
criteria for CAC screening in patients with stroke based on the
presence of risk factors and cerebral atherosclerosis.
MATERIALS AND METHODS
Study Population
Our study involved consecutive patients with acute ischemic
stroke or transient ischemic attack who had been admitted to
the hospital within seven days after the onset of symptoms. All
admitted patients were evaluated using a standard protocol,
which included brain computed tomography (CT), magnetic
resonance imaging (MRI), cerebral angiographic studies
(CT angiography, magnetic resonance (MR) angiography,
or digital subtraction angiography), standard blood tests,
12-lead electrocardiography, continuous electrocardiography
monitoring during hospitalization in the stroke unit or 24-h
Holter monitoring, echocardiography, and MDCTA (16, 17). All
patient data were entered into a prospective registry. Patients
who had been admitted between January 2007 and August 2015
and had undergone both MDCTA and cerebral angiographic
studies were included in the present study.
MDCTA was indicated when the patient fulfilled at least
one of the following criteria: (1) presence of atherosclerosis in
the intracranial or extracranial cerebral arteries; (2) presence
of ≥2 risk factors for CAD such as hypertension, diabetes
mellitus, dyslipidemia, cigarette smoking, or central obesity; and
(3) when the patient’s age is associated with increased risk of
CAD (men >45 years; women >55 years). The exclusion criteria
were as follows: (1) the presence of CAD (i.e., angiographically
confirmed CAD, unstable angina, coronary artery stent, or
angioplasty/coronary artery bypass graft) before index stroke;
(2) high pulse rate (>65/min) that is not controlled using beta-
blockers at the time of MDCTA; (3) poor cooperation; (4)
impaired renal function (estimated glomerular filtration rate
<60 mL/min/1.73 m2 or history of chronic kidney disease);
and (5) failure to obtain informed consent (6, 18). Patients
who were diagnosed to have significant CAD on MDCTA were
consulted or referred to cardiologists for further evaluation
and management. Some of them were treated with elective
coronary revascularization.
The present study was approved by the Institutional Review
Board of Severance Hospital, Yonsei University Health System
(Seoul, South Korea). Informed consent for this study was waived
due to the retrospective nature of the analysis.
Assessment of CAC Score and Coronary
Artery Disease
Patients underwent MDCTA within 2 weeks after admission,
using a second-generation dual-source CT scanner (Somatom
Definition Flash; Siemens Medical Solutions, Erlangen,
Germany) with prospective electrocardiographic gating,
330-ms gantry rotation time, and a 120-kV tube. A beta-
blocker (40mg propranolol hydrochloride) was administered
1–2 h before the examination of patients with a resting pulse
rate >65/min. Volume-rendered images, curved multiplanar
images, and routine cardiac axis views were obtained using a
dedicated workstation (Wizard; Siemens Medical Solutions) and
interpreted by independent cardiac radiologists.
CAC was identified as a high-attenuation area (exceeding
the threshold of 130 Hounsfield units in a minimum of
three contiguous pixels) in the coronary artery. CAC scores
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were calculated according to the Agatston method (19) semi-
automatically by cardiac radiologists during routine practice
and were included in a formal report on coronary artery CT
angiography. Patients were categorized into the following four
subgroups based on their CAC scores: 0, 0.1–99.9, 100–399.9, and
≥400 (15, 20).
The presence of stenosis was determined at four main
coronary branches: left main, left anterior descending, left
circumflex, and right coronary arteries. The severity of
obstructive CAD was primarily categorized as follows: no
CAD, mild CAD (<50% stenosis), one-vessel disease, two-vessel
disease, and three-vessel disease. One-, two-, or three-vessel
disease is determined based on the number of arteries with
significant stenosis (≥50%) among the three major coronary
arteries (left anterior descending, left circumflex, and right
coronary arteries). Severe CAD was defined as three-vessel
disease or ≥50% stenosis in the left main artery based on
the current treatment guideline for stable coronary artery
disease (21).
Assessment of Cerebral Atherosclerosis
Abnormalities observed during cerebral angiography were
confirmed at a weekly stroke conference, based on a
neuroradiologist’s report and the consensus of stroke specialists.
The degree of stenosis was evaluated using the North American
Symptomatic Carotid Endarterectomy Trial and Warfarin vs.
Aspirin for Symptomatic Intracranial Disease method (22, 23).
The degree of stenosis was estimated in the carotid, vertebral,
basilar, anterior cerebral, middle cerebral, and posterior cerebral
arteries. When multiple stenotic lesions were present in one
artery, data from the most severe lesion were used. Significant
stenosis in cerebral artery atherosclerosis was defined as
atherosclerotic stenosis ≥50% or an obstruction.
Data Analysis and Statistics
Statistical significance was set at P<0.05. IBM SPSS Statistics for
Windows (version 26.0, SPSS Inc., Chicago, IL, USA), R version
3.4.4, and MedCalc Statistical Software version 19.1.3 (MedCalc
Software bvba, Ostend, Belgium; https://www.medcalc.org; 2019)
were used for statistical analysis. All continuous data were
expressed as mean ± standard deviation or median with
interquartile range (IQR), and all categorical data were presented
as numbers (percentages). Independent sample t-tests and
Pearson χ2 tests were used to compare risk factors and the
severity and location of cerebral artery atherosclerosis among the
CAC score subgroups. Enrolled patients were randomly assigned
to two different sets, a set for developing criteria and a set
for validation.
Developing Selection Criteria for Performing CAC
Scan
To determine which patients are at high risk of severe
CAD, logistic regression analysis was performed. Odds ratios
(ORs) with 95% confidence intervals (CIs) were calculated to
estimate the risk associated with a particular variable, based on
binomial distributions.
For the clinical factors, covariates included the presence of
classic vascular risk factors and laboratory results. Statistically
significant continuous variables in univariate logistic regression
were transformed into binomial categorical variables using cut-
off values deriving by ROC curve analysis.
For the arterial factors based on cerebral artery
atherosclerosis, we used the presence of arterial stenosis as
a covariate for univariate analysis. According to the results from
univariate logistic regression analysis, we categorized cerebral
arteries into two subgroups: the intracranial branches (middle
cerebral artery [MCA], anterior cerebral artery [ACA], and
posterior cerebral artery [PCA]) and cervicocephalic branches
(internal carotid artery [ICA] and vertebrobasilar artery [VBA]).
The number of arteries with significant stenosis in each group
was examined in terms of the association with severe CAD for
determining selection criteria for CAC screening.
Statistically significant variables resulting from multivariate
logistic regression analysis were selected to determine the
selection criteria for CAC screening. Finally, we developed simple
selection criteria by combining the results of the analysis of
clinical factors and cerebral atherosclerosis. The values of AUC of
clinical factors, arterial factors, CAC score, and combined criteria
were compared. Youden’s J statistics using ROC curve analysis
were used for determining the cut-off criterion of the selection
criteria for performing a CAC scan.
Validating Selection Criteria
To test the efficacy of selection criteria, ROC curve analysis to
predict severe CAD was done in the separate validation set.
RESULTS
Study Population
Among the 5,745 patients admitted during the study period,
3,479 patients (60.6%) underwent MDCTA. After excluding
patients without available CAC scores (780 patients) and
those without cerebral angiographic data (41 patients), a
total of 2,658 patients (46.2%) were finally included in
the analysis. Enrolled patients were older and mostly male
(P < 0.001). Hypertension, diabetes mellitus, dyslipidemia,
metabolic syndrome, and peripheral artery disease were common
among the enrolled patients (Supplementary Table 1), mainly
attributable to the predetermined criteria for performing
coronary CTA.
Themean age of the 2,658 patients enrolled in the study was 65
± 11 years (range: 17–96). Among these patients, 1,745 patients
were men (65.7%). Coronary artery disease with ≥50% stenosis
in at least one coronary artery was detected in 1,382 patients
(52%). Six hundred and fifty-eight patients (24.8%) had one-
vessel disease, while 364 patients (13.7%) had two-vessel disease.
Severe CAD (three-vessel disease or left main coronary artery
disease) was present in 360 patients (13.5%). The median CAC
score was 66.65 (IQR 3.40–282.25).
Enrolled patients were randomly assigned to two sets; a
set for developing selection criteria for performing CAC scan
(N = 1,860) and a set for testing its efficacy (N = 798) to
predict severe CAD. There was no statistical difference between
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TABLE 1 | Demographic differences between the set for developing criteria and









Age 65.5 ± 11.1 64.7 ± 11.2 0.078







CAC score 0 346 (18.6) 139 (17.4)
0 < CAC score < 100 698 (37.5) 327 (41.0)
100 ≤ CAC score < 400 457 (24.6) 183 (22.9)
CAC score ≥ 400 359 (19.3) 149 (18.7)
Severe coronary artery disease 256 (13.8) 104 (13.0) 0.658
Risk factors
Hypertension 1416 (76.1) 607 (76.1) 1
Diabetes mellitus 612 (32.9) 262 (32.8) 1
Dyslipidemia 247 (13.3) 92 (11.5) 0.239
Smoking 491 (26.4) 234 (29.3) 0.132
Metabolic syndrome 786 (42.3) 347 (43.5) 0.587
Atrial fibrillation 242 (13.0) 97 (12.2) 0.587
Laboratory findings
Total cholesterol 183.4 ± 61.5 182.7 ± 64.9 0.807
Triglyceride 129.1 ± 95.0 127.2 ± 84.2 0.618
HDL cholesterol 42.3 ± 10.6 42.2 ± 11.1 0.759
LDL cholesterol 108.7 ± 35.4 107.9 ± 35.8 0.631
HbA1c 6.7 ± 3.5 6.5 ± 1.4 0.051
CRP 13.2 ± 32.0 11.5 ± 29.8 0.442
hs-CRP 6.9 ± 18.8 6.6 ± 21.6 0.741
Initial glucose 142.7 ± 62.5 140.7 ± 56.3 0.421
Fasting glucose 115.6 ± 41.5 116.9 ± 70.1 0.621
Initial systolic BP 155.7 ± 39.7 155.6 ± 31.0 0.903
Initial diastolic BP 85.6 ± 15.5 86.6 ± 16.3 0.161
Previous cerebral infarction 250 (13.4) 113 (14.2) 0.665
Peripheral artery disease 45 (2.4) 13 (1.6) 0.257
Values are presented as the mean ± standard deviation or number (%), except
CAC score*.
CAC scores* are presented as the median (interquartile range).
BP, blood pressure; CAC, coronary artery calcium; HbA1c, hemoglobin A1c;
HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-
density lipoprotein.
the two sub-population in terms of basic demographic factors,
distribution of CAC scores, and frequency of cardiovascular risk
factors, and mean laboratory values (Table 1).
Developing Selection Criteria
Predicting Severe Coronary Artery Disease Using the
CAC Score
Among 1,860 patients in the set for developing selection criteria,
coronary artery disease with ≥50% stenosis in at least one
coronary artery was detected in 983 patients (52.8%). Severe CAD
(three-vessel disease or left main coronary artery disease) was
present in 256 patients (13.8%). The CAC score was significantly
FIGURE 1 | Coronary calcium score related to the severity of coronary artery
disease. Coronary calcium scores (CAC) significantly increased as coronary
artery severity increased. CAC was shown as the median and interquartile
ranges. CAC, coronary artery calcium; LM, left main; VD, vessel disease.
TABLE 2 | Coronary artery calcium score correlated with severe coronary artery
disease.
Odds ratio (95% CI) P
CAC group
CAC score 0 Reference
0 < CAC score < 100 6.77 (2.08–22.05) 0.002
100 ≤ CAC score < 400 16.95 (5.27–54.55) <0.0001
CAC score ≥ 400 86.87 (27.35–275.88) <0.0001
CAC, coronary artery calcium; CI, confidence interval.
higher in the patients with severe CAD (median 554.4, IQR
202.7–1198.0) compared with the patients without severe CAD
(median 48.2, IQR 1.0–195.2, P < 0.001). The CAC score
increased as CAD severity (Figure 1). The CAC score of each
subgroup was significantly correlated with the severe CAD and
the strength of this correlation increased as the CAC score
increased (Table 2).
Factors Associated With Severe CAD
Classic vascular risk factors and laboratory results
In univariate logistic regression analysis, severe CAD was
associated with old age, male sex, dyslipidemia, peripheral
artery disease, previous history of cerebral infarction, high levels
of fasting glucose, and low levels of high-density lipoprotein
cholesterol (Table 3). The age of 65 years was the cut-off for
predicting severe CAD in the ROC curve analysis. Severe CAD
was independently associated with age, male sex, dyslipidemia,
and peripheral artery disease in the multivariate logistic
regression analysis (Table 3). These clinical factors (including
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TABLE 3 | Association between severe coronary artery disease and clinical factors.
Univariate analysis Multivariate analysis* Multivariate analysis
†
Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
Age 1.05 (1.04–1.06) <0.0001 1.06 (1.04 −1.07) <0.0001
Age (>65) 2.45 (1.83–3.28) <0.0001 2.62 (1.93–3.55) <0.0001
Sex (male) 1.59 (1.18–2.14) 0.002 1.95 (1.42–2.67) <0.0001 1.81 (1.33–2.46) <0.0001
Risk factors
Hypertension 1.6 (1.14–2.26) 0.007 1.32 (0.92–1.88) 0.134 1.40 (0.98–2.00) 0.062
Diabetes mellitus 1.39 (1.06–1.83) 0.017 1.09 (0.78–1.50) 0.623 1.21 (0.89–1.66) 0.232
Dyslipidemia 1.68 (1.19–2.37) 0.003 1.81 (1.25–2.61) 0.002 1.77 (1.25–2.61) 0.002
Smoking 1.11 (0.82–1.49) 0.5
Metabolic syndrome 0.96 (0.74–1.26) 0.766
Peripheral artery disease 3.62 (1.94–6.77) <0.0001 2.32 (1.19–4.51) 0.014 2.64 (1.37–5.06) 0.004
Previous cerebral infarction 1.6 (1.13–2.27) 0.008 1.39 (0.97–2.00) 0.073 1.32 (0.92–2.53) 0.133
Laboratory findings
HbA1c 1.00 (0.95–1.04) 0.845
Initial glucose 1.00 (1.00–1.00) 0.137
Fasting glucose 1.00 (1.00–1.00) 0.008 1.01 (1.00–1.01) 0.008
Fasting glucose (>113mg/dl) 1.32 (1.01–1.73) 0.04 1.19 (0.88–1.62) 0.26
C-reactive protein 1.01 (1.00–1.01) 0.296
hs-CRP 1.00 (1.00–1.01) 0.479
Total cholesterol 1.00 (1.00–1.00) 0.703
Triglyceride 1.00 (1.00–1.00) 0.941
HDL cholesterol 0.99 (0.97–1.00) 0.029 0.99 (0.98–1.01) 0.331
HDL cholesterol (≤41mg/dl) 1.34 (1.03–1.75) 0.031 1.23 (0.93–1.62) 0.144
LDL cholesterol 1.00 (1.00–1.01) 0.427
*Was performed with age, levels of laboratory findings as continuous covariates.
†
Was performed with age, fasting glucose, and HDL cholesterol as categorical covariates.
CI, confidence interval; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein.
age >65 years, the male sex, dyslipidemia, and peripheral artery
disease) were used to develop the selection criteria for performing
a CAC scan to screen severe CAD.
Cerebral atherosclerosis
Various degrees of cerebral atherosclerotic stenosis was detected
in 1,389 patients (74.7%) among 1,860 patients. Cerebral
atherosclerosis with significant (≥50%) stenosis at different
locations was detected in 1,021 patients (54.9%). Severe CADwas
significantly associated with significant (≥50%) stenosis in the
BA, VA, and ICA (Table 4). To simplify the criteria, the stenotic
lesion in the VA and BA were combined as VBA.
The association between stenosis of cervicocephalic
branches (VBA and ICA) and severe CAD was significant
and strengthened as the number of arteries with stenosis
increased. However, there was no significant association between
stenosis of intracranial branches and severe CAD (Table 4). The
number of cervicocephalic branches with significant stenosis
was determined as the arterial factors of the selection criteria for
performing a CAC scan.
Determination of Selection Criteria for Performing
CAC Scan
We developed criteria to select which stroke patients need to
perform CAC scan based on the results determining clinical and
arterial factors of selection criteria. We included age, sex, and
other variables that were significant in multivariate analyses to
determine elements of the selection criteria combining clinical
and arterial factors (Tables 3, 4). We calculated the odds ratio
of each potential component of the selection criteria combining
clinical and arterial factors for severe CAD (Table 5). The final
selection criteria combining clinical and arterial factors were
age (>65), male sex, dyslipidemia, peripheral artery disease,
and the presence of significant stenosis in the internal carotid
artery or the vertebrobasilar artery. The AUC of selection
criteria (a combination of clinical and arterial factors) for
predicting severe CAD was 0.701, which significantly higher
than that of clinical factors only (0.652) and that of arterial
factors (0.628) (P < 0.001). The AUC of the CAC score
was 0.805. The predictability significantly improved to 0.836
when the CAC score was added to the selection criteria
(P < 0.001, Figure 2).
The cut-off criterion of the selection criteria for CAC
screening was determined as two or more elements among
the selection criteria (a combination of clinical and arterial
factors) based on Youden’s J statistics using ROC curve
analysis (Supplementary Table 2). The sensitivity was
82.03 and the specificity was 48.50. A CAC score ≥100
was the predicting cut-off value for severe CAD by ROC
curve analysis.
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TABLE 4 | Association between cerebral atherosclerosis and severe coronary artery disease.
Univariate analysis Multivariate analysis* Multivariate analysis
†
Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
ACA <50 Reference
≥50 1.69 (0.94–3.03) 0.079
MCA <50 Reference
≥50 1.33 (0.898–1.80) 0.07
PCA <50 Reference
≥50 1.41(0.96–2.05) 0.078
ICA <50 Reference Reference Reference
≥50 3.05 (2.26–4.11) <0.0001 2.87 (2.12–3.88) <0.0001 2.79 (2.06–3.78) <0.0001
BA <50 Reference Reference
≥50 1.96 (1.15–3.34) 0.013 1.80 (1.05–3.09) 0.033
VA <50 Reference Reference
≥50 2.11 (1.58–2.81) <0.0001 1.90 (1.41–2.54) <0.0001
VBA <50 Reference Reference
≥50 2.30 (1.74–3.04) <0.0001 2.08 (1.57–2.76) <0.0001
Number of arteries with significant stenosis
Intracranial branches 0 Reference
1 1.41 (1.06–1.88) 0.019
2 1.52 (0.82–2.83) 0.187
3 3.06 (0.78–11.94) 0.108
Cervicocephalic branches 0 Reference
1 2.31 (1.74–3.08) <0.0001
2 5.43 (3.42–8.61) <0.0001
* was performed with BA and VA as separate covariates.
†
was performed with VBA as a covariate.
ACA, anterior cerebral artery; BA, basilar artery; CAC, coronary artery calcium; CI, confidence interval; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior cerebral
artery; VA, vertebral artery; VBA, vertebrobasilar artery.
Testing Selection Criteria for Performing
CAC Scan
In the validation set, the AUC value of selection criteria for
predicting severe CAD was 0.661 (Figure 3). The AUC value of
the selection criteria with a CAC score was 0.860 (Figure 3). It
was higher than the predictability of a CAC score alone (the AUC
value 0.833) or selection criteria alone (0.661, P < 0.001).
DISCUSSION
In this study, we first showed that the CAC score was correlated
with CAD severity. We then demonstrated that severe CAD
was associated with clinical factors (age >65 years, male sex,
dyslipidemia, and peripheral artery disease) and arterial factors
(presence of significant stenosis in cervicocephalic branches
(ICA or VBA). Finally, we determined the optimal selection
criteria for CAC evaluation in stroke patients, which was a
combination of clinical and arterial factors. The cut-off criterion
of the selection criteria were two or more factors of the selection
criteria. Furthermore, a CAC score ≥100 predicted severe CAD
in patients with acute stroke in the development set. In the
validation set, severe CAD predictability of the selection criteria
with a CAC score was higher than a CAC score alone.
TABLE 5 | Adjusted Odds ratio with selected factors for developing selection
criteria.
Odds ratio (95% CI) P
Age (>65) 2.36 (1.74–3.20) <0.0001
Sex (male) 1.66 (1.22–2.27) 0.001
Dyslipidemia 1.73 (1.21–2.50) 0.003
Peripheral artery disease 2.76 (1.41–5.41) 0.003
ICA stenosis (≥50%) 2.42 (1.77–3.30) <0.0001
VBA stenosis (≥50%) 1.92 (1.44–2.57) <0.0001
CI, confidence interval; ICA, internal carotid artery; VBA, vertebrobasilar artery.
Current guidelines do not recommend screening tests for the
evaluation of CAD in asymptomatic populations (24). However,
evidence regarding this in stroke patients is still scarce. Among
stroke patients with asymptomatic CAD, major vascular events
are frequent in those who are diagnosed with CAD via coronary
angiography (7). In a study involving 1,893 patients with acute
ischemic stroke, asymptomatic CAD detected via coronary
MDCTA was associated with an increased risk of vascular events
or death during long-term follow-up (18). Propensity score
matching analyses in patients with acute ischemic stroke showed
Frontiers in Neurology | www.frontiersin.org 6 March 2020 | Volume 11 | Article 206
Choi et al. CAC Screening in Cerebral Infarction
FIGURE 2 | Severe coronary artery disease predictability in the development
set. The AUC value of the selection criteria ± the CAC score for predicting
severe CAD was 0.836. It was significantly higher than that of a CAC score
alone (0.805), clinical factors only (0.652), arterial factors only (0.628), and the
selection criteria (a combination of clinical and arterial factors, 0.701).
P < 0.001 for all comparisons. AUC, area under the curve; CAC, coronary
artery calcium; CAD, coronary artery disease.
that vascular events and death were less frequent among those
who had undergone MDCTA than in those who had not during
the follow-up period (25). These findings suggest that screening
to evaluate asymptomatic CAD may be beneficial in a subgroup
of patients with acute cerebral infarction.
The Framingham risk score is commonly used to predict
CAD (26, 27). It is a multivariable statistical model that uses
a risk factor-based paradigm, which includes variables such as
age, sex, smoking, total cholesterol, LDL cholesterol, systolic
blood pressure, and pharmacological treatments for high blood
pressure. The current American Heart Association guideline
recommends the use of the pooled cohort equations to assess the
10-years atherosclerotic cardiovascular disease risk (28).
The Predicting Asymptomatic Coronary Artery Disease in
Patients with Ischemic Stroke and Transient Ischemic Attack
(PRECORIS) score considers the presence and severity of
cervicocephalic arterial stenosis, in addition to the Framingham
risk score. The PRECORIS score was useful for detecting CAD
in patients with stroke (4, 29). We also showed that the risk
of CAD was high in stroke patients with multiple risk factors
in addition to the presence of atherosclerosis of the carotid
and/or vertebrobasilar arteries (6). These findings suggest that
the consideration of both the risk factors and the presence of
cervicocephalic arterial stenosis helps to predict CAD in patients
with stroke better. Patients with acute stroke routinely undergo
cerebral angiography. Therefore, information on the stenosis of
cervicocephalic arteries can be easily obtained. In the present
FIGURE 3 | Severe coronary artery disease predictability in the validation set.
The AUC value of the selection criteria ± the CAC score for predicting severe
CAD was 0.860. It was significantly higher than that of a CAC score alone
(0.833), clinical factors only (0.623), arterial factors only (0.587), and the
selection criteria (a combination of clinical and arterial factors, 0.661).
P < 0.001 for all comparisons. AUC, area under the curve; CAC, coronary
artery calcium; CAD, coronary artery disease.
study, we showed that the use of simple criteria based on the
number of risk factors and the significance of stenosis of the
cervicocephalic arteries could help to determine whether CAC
screening is required or not. These criteria may be useful in daily
clinical practice.
Cardiac CTA is a sensitive and specific diagnostic tool
for CAD. However, it is not recommended for screening
asymptomatic CAD because of the potentially harmful side
effects (30). Cardiac CTA requires the administration of contrast
agents, which limits its use in patients with chronic kidney
disease. These contrast agents have been associated with
idiosyncratic side effects. Beta-blockers are also often required for
heart rate control. CAC scores obtained via non-contrast cardiac
CT have been widely utilized for the prediction of ischemic
heart disease (30). Although coronary CTA is superior to CAC
for the prediction of major cardiovascular events (13), CAC
measurement is non-invasive, does not require the use of contrast
agents, and can be performed very rapidly and efficiently.
The present study has some limitations. First, CAC scores in
our study population may have been higher than those in the
general population, since all enrolled patients had experienced
a stroke or transient ischemic attack and had risk factors that
indicate the necessity for coronary CTA. Second, this study was
based on data obtained from a single hospital-based registry, in
which all patients were of the same ethnicity. Since the prevalence
and risk of CAD and cerebral atherosclerosis may differ among
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patients with different ethnicities and those in different countries
(25), caution should be applied when generalizing our results
to other populations. The results are conditional on subjects
prejudged to be at high risk for atherosclerotic coronary events by
virtue of the presence of atherosclerosis in intra- or extracranial
cerebral arteries. Further studies are required to validate our
findings in other study populations. Third, potential selection
bias presents in this study because MDCTA was indicated in
patients with high risks of CAD.
In conclusion, our findings suggest that the necessity for
CAC evaluation can be determined based on the presence of
clinical risk factors and significant stenosis of the cervicocephalic
arteries in acute ischemic stroke patients. CAC evaluation may
be useful for predicting the severity of CAD in patients with
ischemic stroke.
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